Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel coronavirus (SARS‐CoV‐2) infection in these patients is currently lacking, the COVID‐19 pandemic represents a significant challenge for haemoglobinopathy patients, their families and their attending physicians.
TIF has developed a Position Statement on COVID-19 and Thalassaemia, in which the Federation reflects on general considerations and levels of risk for patients, the adaptation of haemoglobinopathy care, the blood transfusions safety and the blood supply challenges.
This Position Statement was published in the latest issue of the European Journal of Hematology.
Read the TIF Position Statement on COVID-19 & Haemoglobinopathies HERE
Read all TIF’s Publications on COVID-19 HERE